Prism BioLab

About:

Prism develops therapeutic drugs that cure intractable diseases using unique peptide mimic technology.

Top Investors: Eli Lilly, DBJ Capital, JAFCO, Eisai, Innovation Network Corporation of Japan

Description:

PRISM provider of a therapeutic treatment for non-oncology indications.The company develops therapeutic agents that are used to cure pulmonary fibrosis, cancer and incurable diseases.

Total Funding Amount:

$42.1M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Fujisawa, Kanagawa, Japan

Founded Date:

2006-11-02

Founders:

Takehara Dai

Number of Employees:

11-50

Last Funding Date:

2024-01-24

IPO Status:

Private

Industries: